| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $184.6M | +51.4% |
| SG&A Expense | $67.5M | +36.7% |
| Operating Income | -$252.1M | -47.1% |
| Interest Expense | $6.6M | +1.5% |
| Net Income | -$246.3M | -48.6% |
| EPS (Basic) | -$2.47 | -24.1% |
| EPS (Diluted) | -$2.47 | -24.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $177.9M | +74.6% |
| Short-term Investments | $259.4M | +45.7% |
| Current Assets | $451.2M | +56.5% |
| Total Assets | $474.9M | +52.7% |
| Current Liabilities | $46.9M | +43.4% |
| Long-term Debt | $50.1M | -1.7% |
| Total Liabilities | $106.3M | +23.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$200.9M | -38.4% |
| Capital Expenditures | $98K | +38.0% |
| Investing Cash Flow | -$76.1M | -284.9% |
| Financing Cash Flow | $353.0M | +244.2% |
| Free Cash Flow | -$201.0M | -38.4% |
| Stockholders' Equity |
| $368.6M |
| +63.7% |